You are in: eMedicine Specialties > Infectious Diseases > MEDICAL TOPICS Propionibacterium InfectionsArticle Last Updated: Apr 27, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Sajeev Handa, MB, BCh, BAO, LRCSI, LRCPI, Director, Division of Hospitalist Medicine, Department of Medicine, Rhode Island Hospital Sajeev Handa is a member of the following medical societies: Infectious Diseases Society of America and Society of Hospital Medicine Editors: Douglas A Drevets, MD, Assistant Professor, Department of Medicine, Section of Infectious Disease, Oklahoma University Health Sciences Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Aaron Glatt, MD, Professor of Clinical Medicine, New York Medical College; Chief Medical Officer, Departments of Medicine and Infectious Diseases, New Island Hospital; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital Author and Editor Disclosure Synonyms and related keywords: Propionibacterium acnes, P acnes, Propionibacterium granulosum, P granulosum, Propionibacterium avidum, P avidum, Propionibacterium propionicus, P propionicus pustular acne, acne vulgaris, cystic acne, nodular acne, acneiform drug eruptions INTRODUCTIONBackgroundPropionibacterium species are inhabitants of the skin and usually are nonpathogenic. As a result, they are common contaminants of blood and body fluid cultures. These species are slow-growing, nonsporulating, gram-positive anaerobic bacilli. Propionibacterium species belong to the genera of Coryneforms and are the best studied because of their association with acne vulgaris. However, a number of other infections may be caused by Propionibacterium species, and these are described briefly in this article. Propionibacterium acnes is found briefly on the skin of neonates, but true colonization begins during the 1-3 years prior to sexual maturity when numbers rise from fewer than 10/cm2 to about 106/cm2, chiefly on the face and upper thorax. In the lipid-rich microenvironment of the hair follicle, P acnes produces inflammatory mediators that result in papules, pustules, and later, nodulocystic lesions that are typical of inflammatory acne. Propionibacterium granulosum is found in the same areas but at numbers about one hundredth of those of P acnes. Both P acnes and P granulosum may be isolated from the gastrointestinal tract. Propionibacterium avidum is found in the axilla, rather than on exposed areas, and increases in numbers at puberty. Propionibacterium propionicus has been implicated as a less common causative agent of a disease process similar to actinomycosis. The most common cause of actinomycosis is Actinomyces israeli. FrequencyUnited StatesAcne vulgaris is sufficiently common that it may be considered physiologic. RaceAcne appears to be a familial condition and is less common in Japanese people than in the white American population. SexIn girls, acne may precede menarche by more than 1 year. The greatest number of cases is observed during the middle-to-late teenage period, and incidence decreases subsequently. Males are affected more frequently than females are, and males tend to have more severe involvement. AgeAcne vulgaris is a self-limited disease involving the sebaceous follicles observed primarily in adolescents. Occasionally, it is present at birth, and mild cases may be observed in the neonatal period. During puberty, acne typically becomes a common problem. The condition often is an early manifestation of puberty. In very young patients, the predominant lesions are comedones, and inflammatory lesions are rare. CLINICALHistory
DIFFERENTIALSActinomycosis Behcet Disease Cryptococcosis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Tretinoin (Retin-A, Avita) |
|---|---|
| Description | Inhibits microcomedo formation and eliminates lesions present. Makes keratinocytes in sebaceous follicles less adherent and easier to remove. Available as 0.025%, 0.05%, and 0.1% creams. Available also as 0.01% and 0.025% gels. |
| Adult Dose | Begin with lowest tretinoin formulation and increase as tolerated; apply hs or qod; reduce frequency of application if irritation develops |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity increases with coadministration of benzoyl peroxide, salicylic acid, and resorcinol; avoid topical sulfur, resorcinol, salicylic acid, other keratolytics, abrasives, astringents, spices, and lime |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Photosensitivity may occur with excessive sunlight exposure; caution in eczema; not to be applied to mucous membranes, mouth, and angles of nose |
| Drug Name | Benzoyl peroxide (Benzac, Benoxyl) |
|---|---|
| Description | Free-radical oxygen is released upon administration and oxidizes bacterial proteins in sebaceous follicles, decreasing the quantity of irritating free fatty acids and of anaerobic bacteria. It also has keratolytic and comedolytic effects. This agent is most effective for inflammatory acne. It is available OTC and by prescription. |
| Adult Dose | Apply sparingly qd; gradually increase to bid/tid prn; reduce dose, frequency, or concentration if excessive dryness or peeling occurs |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Potentiates adverse effects of tretinoin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Avoid contact with lips, eyelids, mucous membranes, and eyes; for external use only; discontinue if swelling, burning, or excessive dryness occurs |
| Drug Name | Azelaic acid (Azelex, Finevin) |
|---|---|
| Description | Has been shown to help normalize keratinization and to reduce proliferation of P acnes and has proven to be effective against both noninflammatory and inflammatory lesions. This medication may decrease microcomedo formation in acne vulgaris and may have a bleaching effect on skin. May also have antimicrobial effect. Efficacy may be enhanced when used in combination with other topical medications (eg, benzoyl peroxide, clindamycin, tretinoin). Hands should be washed following application. Duration of treatment can vary from person to person and varies depending on severity. Improvement occurs in the majority of patients with inflammatory lesions within 4 wk. |
| Adult Dose | Wash area and apply sparingly bid; duration of use can vary from person to person and depends on severity of acne |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Avoid contact with eyes; discontinue use if severe irritation develops; adverse reactions generally are mild and transient; most common adverse reactions (occurring in approximately 1-5% of patients) are pruritus, burning, stinging, and tingling |
| Drug Name | Tazarotene (Tazorac, Avage) |
|---|---|
| Description | Retinoid prodrug whose active metabolite modulates differentiation and proliferation of epithelial tissue; may also have anti-inflammatory and immunomodulatory properties. This agent is strictly contraindicated in pregnancy. |
| Adult Dose | Apply thin film (ie, 2 mg/cm2) hs to clean, dry skin where acne appears |
| Pediatric Dose | Children: Not established Adolescents: Apply as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Do not use concomitantly with dermatologic drugs or cosmetics that have a strong drying effect on the skin (eg, salicylic acid, benzoyl peroxide, astringents) |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | May cause burning or stinging; discontinue upon excessive irritation; rinse thoroughly upon contact with eyes, eyelids, or mouth; may cause severe irritation in eczematous skin; photosensitivity may occur |
These agents are useful in papular, pustular, and cystic acne and must be taken for weeks to be effective. They are typically used for many weeks or months to achieve maximum benefit.
Long-term antibiotics may be required and necessitate monitoring for adverse drug events. Females should be warned about the development of vaginitis secondary to Candida albicans.
Topical antibiotics are useful in mild pustular and comedone acne. These preparations include clindamycin, erythromycin, and Benzamycin (erythromycin 3%-benzoyl peroxide 5% gel).
| Drug Name | Erythromycin (E.E.S., E-Mycin, Eryc) |
|---|---|
| Description | Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. Age, weight, and severity of infection determine proper dosage in children. When bid dosing is desired, half the total daily dose may be taken q12h. For more severe infections, double the dose. |
| Adult Dose | 250 mg erythromycin stearate/base (or 400 mg ethylsuccinate) PO q6h 1 h ac, or 500 mg q12h Alternatively, 333 mg PO q8h; increase to 4 g/d depending on severity of infection |
| Pediatric Dose | 30-50 mg/kg/d (15-25 mg/lb/d) PO divided q6-8h; double dose for severe infection |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (administer doses pc); discontinue use upon nausea, vomiting, malaise, abdominal colic, or fever |
| Drug Name | Minocycline (Minocin) |
|---|---|
| Description | Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma species. |
| Adult Dose | 100 mg PO bid for 5-7 d or longer for acne |
| Pediatric Dose | <8 years: Not recommended >8 years: 4 mg/kg PO initially, followed with 2 mg/kg q12h |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids that contain aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (second half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines; hepatitis or lupuslike syndromes may occur |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. |
| Adult Dose | 75-300 mg PO bid/qid Alternatively, 600 mg IV q8h |
| Pediatric Dose | Not established; 20-40 mg/kg/d IV divided tid/qid suggested |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay effect |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis by allowing overgrowth of Clostridium difficile |
| Drug Name | Vancomycin (Vancocin, Vancoled, Lyphocin) |
|---|---|
| Description | Potent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who cannot receive, or who have failed to respond to, penicillins and cephalosporins or have infections with resistant staphylococci. To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients diagnosed with renal impairment. |
| Adult Dose | 1 g IV q12h (normal renal function) |
| Pediatric Dose | 40 mg/kg/d IV divided tid/qid for 7-10 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in renal failure, neutropenia; red man syndrome is caused by too rapid IV infusion (dose administered over a few min) but rarely happens when dose is administered IV over 2 h or as PO or IP administration; red man syndrome is not an allergic reaction |
| Drug Name | Tetracycline (Sumycin) |
|---|---|
| Description | Inhibits bacterial protein synthesis by binding with 30S and, possibly, 50S ribosomal subunit(s). Tetracycline has anti-inflammatory activity. |
| Adult Dose | 250-500 mg PO q6h Mild-to-moderate infections: 500 mg PO bid or 250 mg PO qid for 7-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 25-50 mg/kg/d (10-20 mg/lb) PO qid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids that contain aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (second half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
These agents are reserved for patients with acne who have clinical signs of androgen excess and for those in whom other treatments have failed. Used in women with treatment-resistant, late-onset, or persistent acne. Some of these women have signs suggestive of hyperandrogenism (eg, hirsutism, irregular menses, menstrual dysfunction), but others are without abnormalities. Serum androgen levels may or may not be elevated.
Three options are available. Estrogen suppresses ovarian androgens (oral contraceptives), glucocorticoids suppress adrenal androgen, and antiandrogens (eg, spironolactone, cyproterone acetate) act at the peripheral level.
| Drug Name | Spironolactone (Aldactone) |
|---|---|
| Description | Aldosterone antagonist inhibits ovarian and adrenal production of androgens. Competes with dihydrotestosterone, binding at hormone receptor sites on hair follicle cells. Also reduces 17-alpha-hydroxylase activity, lowering plasma levels of testosterone and androstenedione. |
| Adult Dose | 200 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; anuria; renal failure; hyperkalemia |
| Interactions | May decrease effect of anticoagulants; potassium and potassium-sparing diuretics may increase toxicity of spironolactone |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in pregnancy-induced hypertension; caution in renal and hepatic impairment |
| Drug Name | Cyproterone (Androcur) |
|---|---|
| Description | Not available in the United States. This is an oral contraceptive that is highly effective in improving acne. An androgen receptor antagonist and weak gonadal androgen production inhibitor. Also a weak progestin. |
| Adult Dose | 2 mg PO qd with either 0.035 or 0.050 mg ethynyl estradiol; clinical benefit can be enhanced by administering 50 or 100 mg PO qd from the 5th to the 14th day of cycle |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; pregnancy and breastfeeding; Dubin-Johnson syndrome; hepatic disease; blood-clotting disorder; Rotor syndrome |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in chronic depression, diabetes with vascular changes, and sickle cell anemia |
Isotretinoin is related to vitamin A and is very effective to control acne and to induce long-term remissions.
| Drug Name | Isotretinoin (Accutane) |
|---|---|
| Description | Oral agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of the naturally occurring tretinoin (trans-retinoic acid). Both agents are structurally related to vitamin A. Isotretinoin decreases sebaceous gland size and sebum production and may inhibit sebaceous gland differentiation and abnormal keratinization. Treatment is weight-based, and the standard course of treatment usually is from 16-20 wk. |
| Adult Dose | 0.5-1.5 mg/kg/d (usually 1 mg/kg/d) PO for 20 wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity may occur with vitamin A coadministration; pseudotumor cerebri or papilledema may occur when coadministered with tetracyclines; isotretinoin may reduce plasma levels of carbamazepine |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | Severity of adverse effects proportional to daily dose; monitor triglyceride levels, LFTs, and CBC counts prior to and during treatment; if triglyceride levels >700-800 mg/dL, discontinue medication to diminish risk of pancreatitis; perform pregnancy test prior to commencing treatment; additional adverse effects include hyperostoses, cheilitis, headache, and amenorrhea |
These agents may modify or inhibit inflammatory process.
| Drug Name | Adapalene (Differin) |
|---|---|
| Description | Modulates cellular differentiation, inflammation, and keratinization. May be tolerated by individuals who cannot tolerate tretinoin creams. A therapeutic response can be expected following 8-12 wk of therapy. Available as 0.1% gel or solution. |
| Adult Dose | Apply hs, some patients may tolerate bid dosing |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None Reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Avoid contact with mucous membranes, eyes, mouth, and nostrils; avoid exposure to sunlight and sunlamps; dryness of skin, scaling, erythema, burning, and pruritus may occur |
| Drug Name | Erythromycin and benzoyl peroxide (Benzamycin) |
|---|---|
| Description | Contains erythromycin, which is a macrolide antibiotic, as well as benzoyl peroxide. Benzoyl peroxide, in addition to being an antibacterial agent, is a keratolytic and desquamative agent. With benzoyl peroxide, free-radical oxygen is released upon administration, oxidizing bacterial proteins in sebaceous follicles and decreasing the number of anaerobic, bacterial, and irritating free fatty acids. Has keratolytic and comedolytic effects. Erythromycin is indicated for infections caused by susceptible strains of microorganisms. |
| Adult Dose | Apply twice daily am and pm to affected areas after skin is washed thoroughly, rinsed with warm water, and gently patted dry |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | For external use only; avoid contact with lips, eyelids, mucous membranes, and eyes; discontinue upon swelling, burning, or excessive dryness |
| Media file 1: Propionibacterium infection. Nodular-cystic acne. | |
View Full Size Image | Media type: Photo |
| Media file 2: Propionibacterium infection. Pustular acne. | |
View Full Size Image | Media type: Photo |
Propionibacterium Infections excerpt
Article Last Updated: Apr 27, 2006